BIO-TECHNE Corp. Files 8-K on Operations and Shareholder Votes

TL;DR

BIO-TECHNE filed an 8-K on 10/25, check it for financial updates and shareholder votes.

AI Summary

On October 25, 2024, BIO-TECHNE Corp. filed an 8-K report detailing the results of its operations and financial condition. The filing also includes information regarding matters submitted to a vote of security holders and other events. The report was filed on October 30, 2024.

Why It Matters

This filing provides investors with crucial updates on BIO-TECHNE Corp.'s financial performance and any significant corporate actions or decisions made by its shareholders.

Risk Assessment

Risk Level: low — This is a routine 8-K filing providing standard corporate information and financial updates, not indicating any immediate or significant risks.

Key Players & Entities

• BIO-TECHNE Corp. (company) — Filer of the 8-K report
• October 25, 2024 (date) — Earliest event date reported
• October 30, 2024 (date) — Date of filing
• Minnesota (location) — State of incorporation
• 614 McKinley Place NE (address) — Principal executive offices
• Minneapolis (location) — City of principal executive offices

FAQ

Filing Documents

• tech-20241025x8k.htm (8-K) — 61KB
• tech-20241025xex99dex991.htm (EX-99.EX-99_1) — 414KB
• tech-20241025xex99dex992.htm (EX-99.EX-99_2) — 21KB
• 0001558370-24-013879.txt ( ) — 646KB
• tech-20241025.xsd (EX-101.SCH) — 3KB
• tech-20241025_lab.xml (EX-101.LAB) — 15KB
• tech-20241025_pre.xml (EX-101.PRE) — 11KB
• tech-20241025x8k_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation (the "Company") on October 30, 2024, describing the results of operations for the quarter ended September 30, 2024 and its financial condition as of September 30, 2024 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders A quorum was present at the Annual Meeting with 148,168,864 shares represented personally or by proxy, which represents approximately 93.39% of the outstanding shares of the Company's common stock. The voting results at the Annual Meeting were as set forth below. Proposal No. 1 – The shareholders voted to set the number of directors at nine: For Against Abstain Broker Non-Vote 147,416,243 587,153 106,653 0 Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors: For Against Abstain Broker Non-Vote Robert V. Baumgartner 135,629,662 7,184,651 108,555 5,187,181 Julie L. Bushman 137,726,895 5,090,472 105,501 5,187,181 John L. Higgins 135,544,819 7,264,115 113,934 5,187,181 Roeland Nusse 141,573,245 1,241,096 108,527 5,187,181 Kim Kelderman 142,088,978 730,531 103,359 5,187,181 Joseph D. Keegan 139,194,251 3,617,533 111,084 5,187,181 Alpna Seth 137,509,635 5,302,948 110,285 5,187,181 Rupert Vessey 140,985,843 1,825,907 111,118 5,187,181 Judith Klimovsky 142,641,977 176,715 104,176 5,187,181 Each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation. Proposal No. 3 – The shareholders adopted a non-binding resolution approving the compensation of the Company's named executive officers, as described in the Proxy Statement: 9, For Against Abstain Broker Non-Vote 122,860,464 19,912,153 150,251 5,187,181 Proposal No. 4 – The shareholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2025. 40 For Against Abstain Broker Non-Vote 34,862,262 856,480 5,701 0

01 Other Events

Item 8.01 Other Events A copy of the press release issued by Bio-Techne Corporation on October 30, 2024, announcing a cash dividend is attached hereto as Exhibit 99.2.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release, dated October 30, 2024, announcing results of operations 99.2 Press Release, dated October 30, 2024, announcing cash dividend 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-TECHNE CORPORATION Date: October 30, 2024 By: /s/ Shane V. Bohnen Shane V. Bohnen Senior Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR